MediciNova, Inc. 2020 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. The filing covers the fiscal year ended December 31, 2020, rather than a standalone fourth quarter. The company has no approved products and no commercial sales or marketing infrastructure.
The principal programs are MN-166 (ibudilast) for progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and COVID-19-related ARDS; MN-001 (tipelukast) for NASH and idiopathic pulmonary fibrosis; and earlier-stage or paused programs MN-221 (bedoradrine) and MN-029 (denibulin).
Financial performance, liquidity and capital resources
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patent expense | $7.5 million | $6.1 million |
| General and administrative expense | $6.7 million | $8.0 million |
| Total operating expenses | $14.2 million | $14.0 million |
| Net loss | $13.9 million | $12.9 million |
| Basic and diluted loss per share | $0.31 | $0.30 |
| Net cash used in operating activities | $10.8 million | $9.1 million |
| Net cash provided by financing activities | $7.1 million | $10.6 million |
| Cash and cash equivalents at year-end | $60.0 million | $63.8 million |
Operating expenses were $14.2 million, producing an operating loss of $14.2 million. Interest income declined to $0.4 million from $1.1 million because of lower interest rates. Accumulated deficit was $382.9 million at year-end. Working capital was $58.5 million and total assets were $75.4 million.
The company reported no traditional funded debt balance in the presented balance sheet. Total liabilities were $4.1 million, including $2.2 million of current liabilities, $1.7 million of long-term deferred revenue and $0.2 million of deferred tax liabilities. Operating lease liabilities totaled approximately $0.2 million at December 31, 2020.
During 2020, MediciNova sold 824,798 shares under its at-the-market facility for $6.4 million of gross proceeds and $6.2 million of net proceeds. On January 29, 2021, it issued 3,656,307 shares in a private placement for approximately $20 million of gross proceeds, or approximately $19.9 million net of issuance costs. Management stated that available working capital was sufficient to fund operations at least through the end of 2022, although future clinical development and financing needs remain uncertain.
Material changes versus 2019
- Research, development and patent expense increased $1.4 million, primarily because of higher clinical trial costs for the MN-166 ALS program.
- General and administrative expense decreased $1.3 million, mainly due to lower performance-based stock compensation and legal expenses.
- Net loss increased by approximately $0.9 million, while loss per share increased from $0.30 to $0.31.
- Operating cash use increased from $9.1 million to $10.8 million, and year-end cash declined by $3.8 million.
- Noncash stock-based compensation decreased from $4.1 million to $3.2 million.
- MN-166 external development expense increased to $4.3 million from $3.2 million. The filing also reported $0.2 million of external expense for a BC-PIV COVID-19 vaccine program in 2020.
- The company continued to increase its common shares outstanding through ATM sales, option exercises and other equity issuance, creating potential dilution.
Programs, outlook and management commentary
- Ongoing programs included Phase 2b/3 ALS, COVID-19 ARDS, degenerative cervical myelopathy, glioblastoma, alcohol dependence, methamphetamine-use biomarker work, chemotherapy-induced peripheral neuropathy, and MN-001 in IPF.
- Management expects research and development expenses to increase in 2021 as development of MN-166 and MN-001 continues.
- The company intends to pursue strategic alliances, non-dilutive grants and potential out-licensing arrangements to support development and commercialization. No strategic commercialization collaboration had been entered into as of the filing.
- MN-221 development is dependent on finding a financially supportive partner following FDA feedback that a pivotal study would need a clinical outcome such as reduced hospitalizations.
- Management reported that COVID-19 temporarily reduced patient visits at certain trial sites but stated that enrollment and routine clinical activities continued and that no material long-term effect on development plans or liquidity was expected based on its assessment at filing.
- Future potential milestone payments were approximately $10.0 million for MN-166 and MN-001 and $33.5 million for other products. Timing is uncertain and depends on development and commercial milestones. Royalties may also be payable on future net sales.
- None of the product candidates has FDA marketing approval. The company expects no product-sales revenue for at least the next several years, if ever.
Key risks and unusual items
- Continued operating losses and dependence on equity financing, partnerships or other capital sources. Failure to obtain funding could require the company to delay programs, out-license assets or cease operations.
- High clinical, regulatory and commercialization risk, including failure to demonstrate efficacy or safety, enrollment delays, clinical holds and rejection of regulatory submissions.
- Reliance on third parties for clinical trials, manufacturing, supply and future commercialization.
- Patent risk is significant: composition-of-matter protection for MN-166, MN-001 and MN-221 has expired or is unavailable, leaving the company more dependent on method-of-use, formulation and other patents.
- Potential dilution from the $75 million 2019 ATM facility, outstanding options for 7.4 million shares and additional shares reserved for equity awards and the employee stock purchase plan.
- Clinical trial accruals of approximately $0.4 million were identified as a critical audit matter because they require judgment regarding vendor progress and unbilled costs.
- Goodwill of $9.6 million and in-process research and development of $4.8 million were not considered impaired under the company’s annual qualitative assessments.
- The company had no material legal proceedings as of the filing date and reported effective disclosure controls and internal control over financial reporting.
Facts an investor should verify
- Current cash runway after the January 2021 private placement and the pace of operating cash burn in subsequent quarterly filings.
- Enrollment, timing, funding and interim or final results for the ALS, COVID-19 ARDS, IPF, alcohol dependence and other ongoing trials.
- Whether any program receives FDA approval, a pivotal-trial agreement, a partnership, licensing payment or milestone payment.
- Remaining capacity under the 2019 ATM facility and the potential dilution from equity awards, option exercises and future financings.
- Whether clinical, regulatory, manufacturing or COVID-19-related disruptions alter management’s stated funding horizon through the end of 2022.
- The validity, remaining term and commercial relevance of method-of-use and other patent protection for the lead candidates.